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ABSTRACT 
     Folate receptor (FR) is overexpressed on the cell membrane in cancer tissues and activated 
macrophages associated with rheumatoid conditions. However, FR is restricted in normal healthy 
tissues. Folic acid has shown high affinity to folate receptors and thus can be used in targeting 
the tumor cells. Folic acid residue, pteroic acid is also used in several studies that are involved in 
targeting cancer cells. Several examples include technetium -99m radiotracer labelled pteroyl-lys 
conjugates(Guo H, Xie F, Zhu M, Li Y, Yang Z, Wang X, Lu J. The synthesis of pteroyl-lys 
conjugates and its application as Technetium-99m labeled radiotracer for folate receptor-
positive tumor targeting. Bio-org Med Chem Lett. 2011 Apr 1;21(7):2025-9), pteroic acid-
conjugated nitroheterocyclic phosphoramidates (Gali Steinberg and Richard F. Borch. Synthesis 
and Evaluation of Pteroic Acid-Conjugated Nitroheterocyclic Phosphoramidates as Folate 
Receptor-Targeted Alkylating Agents. J. Med. Chem., 2001, 44 (1), 69–73). 
 In this project, we were successfully able to conjugate pteroic acid with polyethylene Glycol-
Amine to create an elegant building block(pte-PEG-amine) for synthesis of future imaging 
agents. The compound was purified and analytically tested by HPLC (High Pressure Liquid 
Chromatography) and MS (Mass spectrometry) supporting successful synthesis and purification.  
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INTRODUCTION: 
     Folic acid is a water-soluble B9 vitamin. It is also known as Pteroylglutamic acid. Folic acid is 
not physiologically active but when it is converted to 5-MTHF it becomes active. It plays a 
major role in metabolism of homocysteine and its synthesis, methylation, and repair of DNA 
(folate is used to synthesize thymine)1,2,3. Thus, it has a vital role in cell growth and cell 
proliferation. Insufficiency of folate in the body can result in many health problems. Lack of 
folate may cause an imbalance in DNA precursors, uracil misincorporation into DNA, and 
chromosome breakage4. Once bound to folate receptors that are present on the cell surface, 
invagination of the cell membrane occurs and the compound is internalized through the 
endocytosis process5 given that FR is a membrane bound, glycosylphosphatidylinositol anchored 
glycoprotein(GPI)6.  Folic acid has shown high affinity (KD̴ 10
-10 M) towards surface cell 
oriented receptor.7 Thus, folate conjugates can be used in treatment of tumor and rheumatoid 
arthritis (RA) by attaching payloads to folic acid.  
     Folic acid is a combination of the pteroic acid (pte) (Fig-1) and glutamate (glu) and provides 
two positions for derivatization, the α- and γ-carboxylic acid (Fig-2). The glutamate residue and 
free carboxylic acid group of folic acid are believed to retain binding affinity to Folate 
receptor(FR)7,8,9. These findings debated that Glu moiety of folic acid is responsible FR binding 
and folic acid that lack of Glu moiety at the distal end exhibited poor binding of folate receptor. 
However, further studies had shown that removal of glutamyl carboxylate moiety from folic acid 
had no inhibitory effect on its cell internalization and these pteroic conjugates could also still 
selectively bind to FR+ cancer cells. Mark A Green10 had shown that pteroic acid conjugate 
efficiently targeted FR as clinically studied Folate conjugate.  
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The current research involves purification and analysis of a pteroyl conjugate, pteroic-PEG-
amine(Fig-3). By removing Glutamate moiety, this rapid synthesis allows the building of a 
conjugatable targeting ligand without the complexity of having a conjugatable free carboxylate 
group along with the free amine.   
EXPERIMENTAL PROCEDURE: 
 
Synthesis of pteroic conjugate: 
• 0.0640 g of Universal PEG Nova Tag Resin was placed in syringe and DMF (dimethyl 
formamide) was added to it. Then it was shaken for 20 min and tip off. 20% piperidine 
(in water) was added to the syringe and it was shaken for further 5min to get Fmoc  
(fluorenylmethyloxycarbonyl) off from resin. After shaking, piperidine was squeezed off 
from the syringe. 
• 0.0175g of HATU(1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 
3-oxid hexafluorophosphate) , a peptide coupling reagent,  was added to the syringe that 
contained resin and washed 2-3 times with 20% piperidine and DMF. This solution was 
squeezed in pteroic acid container and added 0.022 ml of DIPEA (N,N-
diisopropylethylamine) to dissolve this substance. 0.5 mL of dimethyl sulfoxide (DMSO) 
also added to container to enhance pteroic acid dissolution. This   whole solution was 
taken into the syringe and was put on shaker for 24 hrs.  
• After 24 hrs, the solvent inside the syringe was removed and again washed with 
DMF(2ml), dichloromethane (2ml), Methanol (2ml).   
• The leftover present in the syringe was washed with 100µL of distilled water and 
trifluoroacetic acid(TFA) and dried. 
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• The dried yield still had MMT (methylcyclopentadienyl manganese tricarbonyl) group on 
it. 1 mL of distilled water and TFA was added to above leftover. The solution became 
orange in color and It was shaken for 2hrs. By this reaction, the MMT group and PEG 
moiety (polyethylene glycol) was cleaved off from the resin.  
• Ether was used and placed in a centrifuge tube and kept in ice bath. The above solution 
was added to ether solvent which finally formed a foggy solution. This mixture was 
centrifuged for 3 min. TFA helps the   compound to be soluble in ether.  
• After centrifugation process, the   solvent was remained above the sediment in centrifuge 
tube. This was decanted from the tube.  
• Argon gas was used to dry the obtained product in centrifuge tube. 9mL of distilled water 
and 10% of ammonium hydroxide (in water) was added to centrifuge tube.  
• This produced the molecule of interest. 
HPLC purification of Pteroic conjugate : 
 
     The crude conjugate was dissolved in DMSO and centrifuged for 10 minutes. The HPLC, 
Hewlett Packard, series 1050 equipped with diode array detector (DAD) and Chemstation 
software was used in this project. RigelTM HPLC, C18 column was used for purification of the 
sample (Reverse phase technique). Size of the of the column was 250 mm ×4.6 mm ×5 m. 
Ammonium bicarbonate, 0.45g, in 500 mL of distilled water (10 mM) is used as a buffer (pH 
7.5).              
Table 1 
 
            SOLVENTS 
 
FLOW RATE RUN TIME 
a) 10mM NH4HCO3 
b)  Acetonitrile (ACN) 
1mL/min 60 min 
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The parameters for solvent gradient was mentioned below. 
 
Table 2 
 
 
 
 
 
 
 
 
 
 
Direct Injection into Agilent 1100 LC/MSD XCT trap 
 
The purified fraction obtained from HPLC was run through LC/MS for further verification of the 
synthesized compound. This was run in positive ion method to generate the results. The 
molecular weight of the compound had Exact mass- 514.27 and Mol.Wt was 514.58. The 
parameters utilized for the methodology are given below. 
Table: 3 
 
 
  
 
 
 
 
 
 
 
 
                Time (min)                    ACN (%) 
0                      1.0 
40 30 
50 60 
55 80 
56 99 
65 99 
  
FLOW RATE 
  
0.5mL/min 
  
SCAN RANGE 
  
  
300-800 m/z 
  
STOP TIME 
  
10 min 
  
  
 SAMPLE 
  
40 µL 
  
NEBULIZER 
  
8 psi 
  
DRY GAS  
  
8 L/min 
  
TEMPEARTURE  
  
300°C 
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                                            Fig 1. Structure of pteroic acid 
 
 
                                          Figure 2.  Structure of folic acid 
 
                                   Fig: 3. Structure of pte-PEG-amine (Exact mass: 514.27) 
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RESULTS AND DISCUSSION: 
 
Fig 4: Chromatogram from HPLC purification of pteroic conjugate. 
 
Purification of the synthesized compound by HPLC resulted a major peak at 25 min. As shown 
in the above figure(Fig.4), the obtained peak confirmed further by DAD Spectrum. DAD 
Spectrum demonstrated pteroic acid character (Fig.5) with maximal absorption taken place at 
280 nm. The desired peak was isolated and collected at 25 min.  
 
 
 
Fig 5: Diode array 
detector results with 
Pteroic acid character 
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Fig:6. Mass Spectrum of Total Ion Chromatogram at 0.2 min for pteroic conjugate 
 
The collected fraction from HPLC purification process was run through LC/MS for further 
identification of synthesized molecule. The above figure (Fig-6) demonstrated the Total ion 
chromatogram which shows a base peak of m/z is 515.3 and it was assumed as molecular ion. 
From the above spectrum, it was understood that proton was associated with the molecule ion 
that corresponded to the synthesized molecule. 
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CONCLUSION: 
 
The pteroic conjugate was successfully synthesized in lab by Dr. Henne. Further, the conjugate, 
pte-PEG-amine was purified and analysed by RP-HPLC (Reverse phase technique). DAD 
spectrum verified isolated fraction of synthesized compound. Then, this fraction was run through 
LC/MS. The mass spectrum of this conjugate was demonstrated at 0.2min in total ion 
chromatogram. It supported the identity of the molecule by showing result in mass spectrum in 
positive ion mode. This building block can be used to attach further to drug delivery systems or 
imaging dyes that are used in studies of cancer and RA.  
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